Individualized dosimetry-based activity reduction of 90 Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
2014
Purpose
Assessment of kidney function evolution after 90Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
44
References
21
Citations
NaN
KQI